SCHEMBL25917431

SCHEMBL25917431

CCOC(=O)CCCCc1cccc2c1cnn2C1CCCCO1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 2/20 0.43
▸ CYP4A11 Q02928 2/20 0.43
▸ TBXAS1 P24557 1/20 0.41
▸ MGLL Q99685 1/20 0.39
▸ HTR4 Q13639 1/20 0.39
▸ CTNNB1 P35222 1/20 0.38
▸ RXRA P19793 1/20 0.38
▸ RXRB P28702 1/20 0.38
▸ RXRG P48443 1/20 0.38
▸ TP53 P04637 1/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ TNF P01375 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30758953 0.87 RXRA (0.39) CYP4F2CYP4A11TBXAS1MGLLHTR4
SCHEMBL24179545 0.86 RXRA (0.46) CYP4F2CYP4A11TBXAS1MGLLHTR4
SCHEMBL30724136 0.85 ALOX5AP (0.39) CYP4F2CYP4A11HTR4CTNNB1RXRA
SCHEMBL25917491 0.85 RXRA (0.37) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL30758979 0.83 RXRA (0.36) CYP4F2CYP4A11TBXAS1MGLLHTR4
SCHEMBL25917544 0.82 CYP4F2 (0.42) CYP4F2CYP4A11TBXAS1MGLLHTR4
SCHEMBL30724046 0.81 RXRA (0.35) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL25918141 0.81 RXRA (0.35) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL25917489 0.80 RXRA (0.40) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL22941287 0.78 RXRA (0.45) CYP4F2CYP4A11RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024006776-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND MEDICAL USE THEREOF RELAY THERAPEUTICS, INC. (US) 2024-01-04 — — WO disclosed
US-20230242507-A1 INDAZOLE-FUSED CYCLIC COMPOUND Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) 2023-08-03 — — US disclosed
US-20230242507-A1 INDAZOLE-FUSED CYCLIC COMPOUND Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242507-A1 INDAZOLE-FUSED CYCLIC COMPOUND SLC5A11, CYP11B2, CYP4F11 CYP4F2 33/4885CYP4A11 4/4885TBXAS1 495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback